🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,187

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

187 results for “Roche” Clear

  1. Columvi 10 mg concentrate for solution for infusion, Glofitamab, Gazyvaro 1,000 mg concentrate for solution for infusion., RoActemra 20 mg/mL concentrate for solution for infusion

    Roche Registration Limited

    Relapsed/refractory B-cell non-Hodgkin’s lymphoma (r/r NHL)

    phase 2 small molecule active

    1 trial

  2. Crovalimab, Crovalimab, Crovalimab Placebo F01-01, Crovalimab

    Roche Registration Limited

    Paroxysmal nocturnal hemoglobinuria (PNH)

    phase 2 small molecule active

    1 trial

  3. DEXAMETHASONE , PEGFILGRASTIM , Mosunetuzumab, DIPHENHYDRAMINE , RASBURICASE , Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, PREDNISONE , FLUDEOXYGLUCOSE (18F) , METHYLPREDNISOLONE, MabThera 500 mg concentrate for solution for infusion, PARACETAMOL, ALLOPURINOL

    Roche Registration Limited

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  4. Delandistrogene moxeparvovec-rokl

    Roche Registration Limited

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  5. Diphenhydramine Hydrochloride Tablets 50 mg, Paracetamol 500mg Tablets, Ocrevus 300 mg concentrate for solution for infusion, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Relapsing-Remitting Multiple Sclerosis (RRMS)

    phase 2 small molecule active

    1 trial

  6. Gazyvaro 1,000 mg concentrate for solution for infusion., CellCept 1 g/5 ml powder for oral suspension, Gazyvaro Placebo, Myfenax 500 mg film-coated tablets

    Roche Registration Limited

    Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  7. IFOSFAMIDE , MabThera 500 mg concentrate for solution for infusion, ETOPOSIDE , Gazyvaro 1,000 mg concentrate for solution for infusion., CD20 CD3 TCB, RoActemra 20 mg/mL concentrate for solution for infusion, CARBOPLATIN

    Roche Registration Limited

    CD20 positive B-Cell Non-Hodgkin Lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  8. INAVOLISIB, DOCETAXEL, INAVOLISIB, ENZALUTAMIDE, ENZALUTAMIDE, ABIRATERONE

    Roche Registration Limited

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  9. INAVOLISIB, FULVESTRANT, INAVOLISIB

    Roche Registration Limited

    Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA)-Mutated, hormone receptor-positive (HR-Positive), human epidermal growth factor receptor 2 (HER2)-Negative Locally Advanced or Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  10. INAVOLISIB, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, Inavolisib placebo, FULVESTRANT

    Roche Registration Limited

    Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8p Loss and Without PIK3CA Mutation

    phase 2 small molecule active

    1 trial

  11. INAVOLISIB, RO 743-5846/F04, RO7223619, INAVOLISIB, RO 743-5846/F07, Ipatasertib, Rozlytrek 200 mg hard capsules, Alecensa 150 mg hard capsules, Rozlytrek 100 mg hard capsules, Tecentriq 1 200 mg concentrate for solution for infusion, INAVOLISIB, Rozlytrek, Ipatasertib, Camonsertib, INAVOLISIB, RO 749-9790/F02-02

    Roche Registration Limited

    Solid tumors

    phase 2 small molecule active

    1 trial

  12. Iberdomide, Iberdomide, Cevostamab, Iberdomide, Revlimid 10 mg hard capsules, RoActemra 20 mg/mL concentrate for solution for infusion, Iberdomide, Revlimid 5 mg hard capsules

    Roche Registration Limited

    Multiple Myeloma (MM)

    phase 2 small molecule active

    1 trial

  13. Kadcyla 160 mg powder for concentrate for solution for infusion., Tecentriq 1,200 mg concentrate for solution for infusion, Perjeta 420 mg concentrate for solution for infusion

    Roche Registration Limited

    Metastatic Cancer

    phase 2 small molecule active

    1 trial

  14. LETROZOLE ACCORD HEALTHCARE 2,5 mg, comprimé pelliculé, Kisqali 200 mg film-coated tablets, RIBOCICLIB, INAVOLISIB, RIBOCICLIB, LETROZOLE, INAVOLISIB, LETROZOLE, Letrozol STADA® 2,5 mg Filmtabletten

    Roche Registration Limited

    Early-Stage, PIK3CA-Mutated Breast Cancer (BC)

    phase 2 small molecule active

    1 trial

  15. Mosunetuzumab

    Roche Registration Limited

    Systemic Lupus Erythematosus (SLE) With or Without Active Lupus Nephritis (LN)

    phase 2 small molecule active

    1 trial

  16. Mosunetuzumab, Mosunetuzumab, Revlimid 5 mg hard capsules, Revlimid 10 mg hard capsules, Mosunetuzumab, Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion

    Roche Registration Limited

    Follicular Lymphoma (FL)

    phase 2 small molecule active

    1 trial

  17. Ocrevus, Ocrevus 920 mg solution for injection, Ocrevus, Ocrelizumab

    Roche Registration Limited

    Multiple Sclerosis (MS)

    phase 2 small molecule active

    1 trial

  18. Placebo RO7269162, RO7269162, RO7269162, RO7269162, FLORBETABEN (18F), FLUTEMETAMOL (18F)

    Roche Registration Limited

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  19. Polivy 30 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab, RoActemra 20 mg/mL concentrate for solution for infusion, Mosunetuzumab, Mosunetuzumab, Polivy 140 mg powder for concentrate for solution for infusion., Mosunetuzumab, Mosunetuzumab

    Roche Registration Limited

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  20. RO7034067

    Roche Registration Limited

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  21. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Roche Registration Limited

    Spinal Muscular Atrophy (SMA)

    phase 2 small molecule active

    1 trial

  22. RO7046015, RO7046015

    Roche Registration Limited

    Early Idiopathic Parkinson’s disease (PD)

    phase 2 small molecule active

    1 trial

  23. RO7197597

    Roche Registration Limited

    Grade 1 Endometrial Cancer

    phase 2 small molecule active

    1 trial

  24. RO7204239, GYM329 Placebo

    Roche Registration Limited

    Facioscapulohumeral muscular dystrophy (FSHD)

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources